share_log

Institutions Profited After Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) Market Cap Rose CN¥684m Last Week but Individual Investors Profited the Most

Institutions Profited After Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) Market Cap Rose CN¥684m Last Week but Individual Investors Profited the Most

上週山東藥玻(SHSE:600529)市值增加6,8400萬元,機構獲利,但個人投資者獲利最多。
Simply Wall St ·  08/05 20:37

Key Insights

主要見解

  • The considerable ownership by individual investors in Shandong Pharmaceutical GlassLtd indicates that they collectively have a greater say in management and business strategy
  • 39% of the business is held by the top 25 shareholders
  • 22% of Shandong Pharmaceutical GlassLtd is held by Institutions
  • 山東藥玻有很多個體投資者持有股份,這意味着他們會共同對該公司的管理和業務策略發表更多意見。
  • 前25名股東持有39%的業務。
  • 22%的山東藥玻股份由機構持有。

If you want to know who really controls Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529), then you'll have to look at the makeup of its share registry. We can see that individual investors own the lion's share in the company with 59% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果你想知道誰真正掌控了山東藥玻股份有限公司(SHSE:600529),那麼你就需要看看它的股權登記簿的構成。我們可以看到,個體投資者擁有該公司的59%所有權,他們將是該股票上漲(或下跌)時受益最多的群體。

Individual investors gained the most after market cap touched CN¥16b last week, while institutions who own 22% also benefitted.

上週市值觸及160億元后,個體投資者獲得了最多的收益,而擁有22%股份的機構也獲益。

Let's take a closer look to see what the different types of shareholders can tell us about Shandong Pharmaceutical GlassLtd.

讓我們更仔細地看看不同類型的股東如何爲我們解釋山東藥玻股份有限公司的情況。

big
SHSE:600529 Ownership Breakdown August 6th 2024
SHSE:600529所有權分佈 2024年8月6日

What Does The Institutional Ownership Tell Us About Shandong Pharmaceutical GlassLtd?

機構持有對山東藥玻股份有限公司有什麼啓示?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

Shandong Pharmaceutical GlassLtd already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Shandong Pharmaceutical GlassLtd's historic earnings and revenue below, but keep in mind there's always more to the story.

山東藥玻股份有限公司的股權登記簿上已經有機構了。他們實際上擁有公司的一部分股份,這意味着在專業投資者中,他們具有一定的可信度,但是,我們不能僅僅依靠這個事實,因爲機構有時會像其他人一樣犯錯誤的投資。當多個機構擁有一支股票時,總會存在他們參與了「擁擠交易」的風險。當這種交易出現問題時,多個機構可能會競相快速賣出股票。這種風險在一個沒有增長曆史記錄的公司中更高。你可以在下面看到山東藥玻股份有限公司的歷史盈利和營業收入,但請記住,這還有更多的故事。

big
SHSE:600529 Earnings and Revenue Growth August 6th 2024
SHSE:600529盈利和營業收入增長 2024年8月6日

We note that hedge funds don't have a meaningful investment in Shandong Pharmaceutical GlassLtd. Looking at our data, we can see that the largest shareholder is Shandong Luzhong Investment Co., Ltd. with 19% of shares outstanding. The second and third largest shareholders are T. Rowe Price Group, Inc. and Hwabao WP Fund Management Co., Ltd, with an equal amount of shares to their name at 3.0%.

我們注意到,對於山東藥玻股份有限公司,對沖基金並沒有具有實質性的投資。從我們的數據來看,最大的股東是山東魯中投資有限公司,持有該公司19%的流通股份。第二和第三大股東是道富集團和華寶WP基金管理有限公司,他們持有相等數量的股份,分別爲3.0%。

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

經過我們的所有權數據研究,我們發現前25位股東共同擁有不到50%的股份,表明沒有任何個人擁有多數利益。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

雖然仔細研究公司的機構持股數據是有意義的,但研究分析師對該股票的看法也是有意義的。有相當數量的分析師在跟蹤該股票,因此了解他們對於未來發展的總體看法可能會有所幫助。

Insider Ownership Of Shandong Pharmaceutical GlassLtd

山東藥玻股份有限公司的內部股東持股不到1%。我們確實注意到,內部人可能通過一個私人公司或其他公司結構間接持有利益。但需要記住的是,它是一個大公司,內部人持有的股票價值爲290萬元人民幣。雖然比例很小,但絕對價值可能更重要。至少有些內部持股總是好的,但檢查這些內部人是否正在出售股票可能也值得一試。

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

在不同國家,內部人員的定義可能會略有不同,但董事會成員始終是內部人員。管理層最終向董事會負責。然而,如果管理人員是創始人或CEO,那麼成爲執行董事會成員也是很常見的。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。

Our information suggests that Shandong Pharmaceutical Glass Co.Ltd insiders own under 1% of the company. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Keep in mind that it's a big company, and the insiders own CN¥2.9m worth of shares. The absolute value might be more important than the proportional share. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.

普通公衆,通常是個體投資者,佔山東藥玻股份有限公司的股份比例爲59%,這表明它是一支相當受歡迎的股票。這種所有權規模爲普通公衆投資者提供了一些集體權力。他們可以,而且可能確實影響公司高管薪酬、股利政策和擬議的商業收購決策。

General Public Ownership

一般大衆所有權

The general public, who are usually individual investors, hold a substantial 59% stake in Shandong Pharmaceutical GlassLtd, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

看來私人公司持有山東藥玻股份有限公司的股份達到了19%。進一步研究這個情況可能是值得的。如果類似內部人這樣的相關方在其中的私人公司中持有利益,那麼這應該在年度報告中予以披露。私人公司可能也對該公司有戰略利益。

Private Company Ownership

私有公司的所有權

It seems that Private Companies own 19%, of the Shandong Pharmaceutical GlassLtd stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

不同的股東群體都持有一家公司的股份,這一點常常值得考慮。但要更好地了解山東藥玻股份有限公司,我們需要考慮許多其他因素。

Next Steps:

下一步:

It's always worth thinking about the different groups who own shares in a company. But to understand Shandong Pharmaceutical GlassLtd better, we need to consider many other factors.

思考持股群體這一點總是有益的。但爲了更好地了解山東藥玻股份有限公司,我們需要考慮許多其他因素。

I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.

我喜歡更深入地了解公司過去的表現。您可以在以下詳細圖表中找到歷史收益和收入。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論